3-fluoro-N-propylaniline | 2806-11-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-fluoro-N-propylaniline
• 英文别名: 3-Fluor-N-propyl-anilin
• CAS: 2806-11-3
• 化学式: C₉H₁₂FN
• mdl: MFCD11144548
• 分子量: 153.199
• InChiKey: DVZIKJQYSRSDKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  光气 、 3-fluoro-N-propylaniline 生成 (3-fluorophenyl)(propyl)carbamic chloride
  参考文献：
  名称：

  FR2234293

  摘要：

  公开号：
• 作为产物：
  描述：

  3-氟苯胺 、 烯丙基丁基醚 在 palladium dichloride 作用下， 以 乙腈 为溶剂， 反应 48.0h， 以58%的产率得到2-ethyl-7-fluoro-3-methylquinoline
  参考文献：
  名称：

  大会替补2 Alkylquinolines由连续钯催化Ç ？N和C ？C键形成

  摘要：

  多样性：可以通过采用温和的反应条件的常规有效合成方法来制备一系列取代的2-烷基喹啉（请参阅方案）。合成是基于连续的钯催化的C ^  N和C  C键的形成，随后进行钯催化的芳构化，并导致在一个步骤中形成所需的化合物。

  DOI：

  10.1002/anie.201102076

文献信息

• Titanium‐Catalyzed Hydroaminoalkylation of Ethylene
  作者：Michael Rosien、Iris Töben、Marc Schmidtmann、Rüdiger Beckhaus、Sven Doye

  DOI：10.1002/chem.201904502

  日期：2020.2.17

  The first examples of titanium-catalyzed hydroaminoalkylation reactions of ethylene with secondary amines are presented. The reactions can be achieved with various titanium catalysts and they do not require the use of high pressure equipment. In addition, the first solid-state structure of a titanapyrrolidine that is formed by insertion of an alkene into the Ti-C bond of a titanaaziridine is reported

  提出了钛与乙烯和仲胺的钛催化的加氢氨基烷基化反应的第一个实例。该反应可以用各种钛催化剂实现，并且它们不需要使用高压设备。另外，报道了通过将烯烃插入到钛氮丙啶的Ti-C键中而形成的钛吡咯烷的第一固态结构。
• [EN] OPTICALLY ACTIVE 1-(FLUORO-,TRIFLUOROMETHYL-OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVES AND PROCESS FOR PRODUCING SAME<br/>[FR] DERIVES DE 1-( PHENYLE A SUBSTITUTION FLUORO,TRIFLUOROMETHYLE OU TRIFLUOROMETHOXY)ALKYLAMINE N-MONOALKYLE OPTIQUEMENT ACTIFS ET LEUR PROCEDE DE PRODUCTION
  申请人：CENTRAL GLASS CO LTD

  公开号：WO2004022521A1

  公开（公告）日：2004-03-18

  An optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy-substituted phenyl)alkylamine N-monoalkyl derivative represented by the formula [4] is produced by a process including (a) reacting an optically active secondary amine, represented by the formula [1], with an alkylation agent R2-X, in the presence of a base, thereby converting the secondary amine into an optically active tertiary amine represented by the formula [3]; and (b) subjecting the tertiary amine to a hydrogenolysis, thereby producing the N-monoalkyl derivative,wherein R represents a fluorine atom, trifluoromethyl group or trifluoromethoxy group, n represents an integer of from 1 to 5, each of R1 and R2 independently represents an alkyl group having a carbon atom number of from 1 to 6, Me represents a methyl group, Ar represents a phenyl group or 1- or 2-naphthyl group, * represents a chiral carbon, and X represents a leaving group.

  通过以下过程制备一种光学活性的1-(氟代、三氟甲基或三氟甲氧基取代的苯基)烷基胺N-单烷基衍生物，其化学式如下[4]：(a) 用碱存在下，将光学活性的二级胺（化学式[1]表示）与烷基化剂R2-X反应，从而将二级胺转化为光学活性的三级胺（化学式[3]表示）；(b) 将三级胺进行氢解作用，从而生成N-单烷基衍生物，其中R代表氟原子、三氟甲基基团或三氟甲氧基团，n代表1至5之间的整数，R1和R2分别代表具有1至6个碳原子的烷基基团，Me代表甲基基团，Ar代表苯基或1-或2-萘基，*代表一个手性碳，X代表一个离去基团。
• Opioid compounds
  申请人：Delta Pharmaceuticals, Inc.

  公开号：US05681830A1

  公开（公告）日：1997-10-28

  Diarylmethyl piperazine compounds having utility as exogenous receptor combinant species for binding with receptors such as delta, mu, sigma, and/or kappa receptors are disclosed. Compounds of the invention may be employed as conjugates in agonist/antagonist pairs for transductional monitoring and assays of neurotransmitter function, and also variously exhibit therapeutic utility, including mediating analgesia, and possessing utility for the treatment of diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depression, asthma, emphysema, cough, and apnea, respiratory depression, cognitive disorders, emesis and gastrointestinal disorders.

  本发明揭示了具有作为外源受体结合物种与诸如δ、μ、σ和/或κ受体结合的效用的二苯甲基哌嗪化合物。该发明的化合物可以作为激动剂/拮抗剂对用于神经递质功能的转导监测和测定中的共轭物，并且还具有各种治疗效用，包括介导镇痛作用，并具有治疗腹泻、尿失禁、精神疾病、药物和酒精成瘾/过量、肺水肿、抑郁症、哮喘、肺气肿、咳嗽和呼吸暂停、呼吸抑制、认知障碍、呕吐和胃肠道疾病的效用。
• Opioid compounds and methods for using same
  申请人：Delta Pharmaceuticals, Inc.

  公开号：US05552404A1

  公开（公告）日：1996-09-03

  Diarylmethyl piperazine compounds having utility as exogenous receptor combinant species for binding with receptors such as delta, mu, sigma, and/or kappa receptors are disclosed. Compounds of the invention may be employed as conjugates in agonist/antagonist pairs for transductional monitoring and assays of neurotransmitter function, and also variously exhibit therapeutic utility, including mediating analgesia, and possessing utility for the treatment of diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depression, asthma, emphysema, cough, and apnea, respiratory depression, cognitive disorders, emesis and gastrointestinal disorders.

  本发明公开了具有作为外源受体组合物种类的功能的二芳基甲基哌嗪化合物，用于与δ、μ、σ和/或κ受体等受体结合。本发明的化合物可以作为激动剂/拮抗剂对共轭体在神经递质功能的转导监测和测定中使用，并且还可以表现出各种治疗效用，包括介导镇痛作用，并具有治疗腹泻、尿失禁、精神疾病、药物和酒精成瘾/过量、肺水肿、抑郁症、哮喘、肺气肿、咳嗽和呼吸暂停、呼吸抑制、认知障碍、呕吐和胃肠道疾病的效用。
• Inhibitors of Histone Deacetylase
  申请人：Moradei Oscar

  公开号：US20080132459A1

  公开（公告）日：2008-06-05

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制组蛋白去乙酰化酶的方法。本发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了用于治疗细胞增殖性疾病和病状的组合物和方法。